IBDEI0NU ; ; 19-NOV-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,10898,1,3,0)
 ;;=3^Personal Hx of Non-Hodgkin Lymphomas
 ;;^UTILITY(U,$J,358.3,10898,1,4,0)
 ;;=4^Z85.72
 ;;^UTILITY(U,$J,358.3,10898,2)
 ;;=^5063436
 ;;^UTILITY(U,$J,358.3,10899,0)
 ;;=Z85.79^^68^676^94
 ;;^UTILITY(U,$J,358.3,10899,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10899,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Lymphoid,Hematpoetc & Rel Tissue
 ;;^UTILITY(U,$J,358.3,10899,1,4,0)
 ;;=4^Z85.79
 ;;^UTILITY(U,$J,358.3,10899,2)
 ;;=^5063437
 ;;^UTILITY(U,$J,358.3,10900,0)
 ;;=Z85.820^^68^676^83
 ;;^UTILITY(U,$J,358.3,10900,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10900,1,3,0)
 ;;=3^Personal Hx of Malig Melanoma of Skin
 ;;^UTILITY(U,$J,358.3,10900,1,4,0)
 ;;=4^Z85.820
 ;;^UTILITY(U,$J,358.3,10900,2)
 ;;=^5063441
 ;;^UTILITY(U,$J,358.3,10901,0)
 ;;=Z85.828^^68^676^98
 ;;^UTILITY(U,$J,358.3,10901,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10901,1,3,0)
 ;;=3^Personal Hx of Malig Neop of Skin
 ;;^UTILITY(U,$J,358.3,10901,1,4,0)
 ;;=4^Z85.828
 ;;^UTILITY(U,$J,358.3,10901,2)
 ;;=^5063443
 ;;^UTILITY(U,$J,358.3,10902,0)
 ;;=Z85.71^^68^676^78
 ;;^UTILITY(U,$J,358.3,10902,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10902,1,3,0)
 ;;=3^Personal Hx of Hodgkin Lymphoma
 ;;^UTILITY(U,$J,358.3,10902,1,4,0)
 ;;=4^Z85.71
 ;;^UTILITY(U,$J,358.3,10902,2)
 ;;=^5063435
 ;;^UTILITY(U,$J,358.3,10903,0)
 ;;=Z65.8^^68^676^138
 ;;^UTILITY(U,$J,358.3,10903,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10903,1,3,0)
 ;;=3^Psychosocial Circumstance Related Problems
 ;;^UTILITY(U,$J,358.3,10903,1,4,0)
 ;;=4^Z65.8
 ;;^UTILITY(U,$J,358.3,10903,2)
 ;;=^5063185
 ;;^UTILITY(U,$J,358.3,10904,0)
 ;;=Z86.11^^68^676^115
 ;;^UTILITY(U,$J,358.3,10904,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10904,1,3,0)
 ;;=3^Personal Hx of Tuberculosis
 ;;^UTILITY(U,$J,358.3,10904,1,4,0)
 ;;=4^Z86.11
 ;;^UTILITY(U,$J,358.3,10904,2)
 ;;=^5063461
 ;;^UTILITY(U,$J,358.3,10905,0)
 ;;=Z86.13^^68^676^82
 ;;^UTILITY(U,$J,358.3,10905,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10905,1,3,0)
 ;;=3^Personal Hx of Malaria
 ;;^UTILITY(U,$J,358.3,10905,1,4,0)
 ;;=4^Z86.13
 ;;^UTILITY(U,$J,358.3,10905,2)
 ;;=^5063463
 ;;^UTILITY(U,$J,358.3,10906,0)
 ;;=Z86.73^^68^676^112
 ;;^UTILITY(U,$J,358.3,10906,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10906,1,3,0)
 ;;=3^Personal Hx of TIA & Cereb Infrc w/o Residual Deficits
 ;;^UTILITY(U,$J,358.3,10906,1,4,0)
 ;;=4^Z86.73
 ;;^UTILITY(U,$J,358.3,10906,2)
 ;;=^5063477
 ;;^UTILITY(U,$J,358.3,10907,0)
 ;;=Z86.79^^68^676^75
 ;;^UTILITY(U,$J,358.3,10907,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10907,1,3,0)
 ;;=3^Personal Hx of Circulatory System Diseases
 ;;^UTILITY(U,$J,358.3,10907,1,4,0)
 ;;=4^Z86.79
 ;;^UTILITY(U,$J,358.3,10907,2)
 ;;=^5063479
 ;;^UTILITY(U,$J,358.3,10908,0)
 ;;=Z91.040^^68^676^64
 ;;^UTILITY(U,$J,358.3,10908,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10908,1,3,0)
 ;;=3^Latex Allergy Status
 ;;^UTILITY(U,$J,358.3,10908,1,4,0)
 ;;=4^Z91.040
 ;;^UTILITY(U,$J,358.3,10908,2)
 ;;=^5063607
 ;;^UTILITY(U,$J,358.3,10909,0)
 ;;=Z98.89^^68^676^120
 ;;^UTILITY(U,$J,358.3,10909,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10909,1,3,0)
 ;;=3^Postprocedural States/Hx of Surgery NEC
 ;;^UTILITY(U,$J,358.3,10909,1,4,0)
 ;;=4^Z98.89
 ;;^UTILITY(U,$J,358.3,10909,2)
 ;;=^5063754
 ;;^UTILITY(U,$J,358.3,10910,0)
 ;;=Z92.3^^68^676^79
 ;;^UTILITY(U,$J,358.3,10910,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,10910,1,3,0)
 ;;=3^Personal Hx of Irradiation
 ;;^UTILITY(U,$J,358.3,10910,1,4,0)
 ;;=4^Z92.3
 ;;^UTILITY(U,$J,358.3,10910,2)
 ;;=^5063637
 ;;^UTILITY(U,$J,358.3,10911,0)
 ;;=Z91.120^^68^676^60
